本帖最后由 老马 于 2012-1-13 21:20 编辑 # n9 e R) B# R6 F- _
; `" e* T6 K: W1 I- T% q5 g爱必妥和阿瓦斯丁的比较- Q4 [) r) X+ J4 e0 A7 i, Z3 q
( p( L( }! L7 x5 Bhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
* ~+ ]% @: c; g( [1 P; r$ e2 a1 X
' D/ N7 N4 p5 D2 O6 A+ y/ A* l' Y
# ^2 m% m6 a Q
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/4 P9 P3 q7 y9 {( B
==================================================
& V% d. ~6 H2 b: S1 wOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)" h1 E7 c4 K3 x, {, F, L' R8 H
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
' t$ Z# r; }: F, CResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.1 b1 f( d# }+ ]& W) |1 @& V
|